Clinical Trials Directory

Trials / Terminated

TerminatedNCT02185937

Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy

Influence of an Acidic Beverage (Coca-Cola) on the Exposure to Imatinib (GLIvec) After Major gastrecTomY in Patients With Gastrointestinal Stromal Tumors (ABILITY)

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
5 (actual)
Sponsor
Radboud University Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The most common sites for GIST to occur are the stomach (60-70%) and proximal small intestines (20-25%). Therefore patients with GIST often have altered GI-tract due to tumor resection or palliative surgery which might affect imatinib exposure. Indeed, Yoo et al. showed that steady state imatinib trough levels in patients with advanced GISTs after major gastrectomy are lower compared to patients with a previous wedge resection or without gastric surgery. Patients that underwent major gastrectomy had an average imatinib plasma trough levels below 1000 µg/L. This while imatinib trough levels above 1000 µg/L are correlated to more beneficial treatment out-comes (longer Progression Free Survival). Since imatinib easily and rapidly dissolves at pH 5.5 or less, a lack of gastric acid secretion might be causing the decreased exposure in the patients that underwent major gastrectomy. Therefore the investigators would like to study if the exposure to imatinib in patients after major gastrectomy can be improved by creating a more acidic environment for absorption through combining imatinib intake with Coca-Cola.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTcolaimatinib intake with coca-cola

Timeline

Start date
2014-08-01
Primary completion
2016-11-01
Completion
2016-11-01
First posted
2014-07-10
Last updated
2020-12-08

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT02185937. Inclusion in this directory is not an endorsement.